CHF Solutions announced that it changed its name to Nuwellis to reflect its focus on pediatric care, critical care and heart failure fluid imbalance.
Eden Prairie, Minn.-based Nuwellis made the change effective on Tuesday, April 27, 2021, and, in conjunction with the name change, changed its ticker symbol on the Nasdaq from CHFS to NUWE, according to a news release.
Nuwellis is meant to be a reflection of the “new well” that the company believes signifies “better tomorrows” for patients, families and providers through the benefits of the company’s Aquadex system.
Aquadex, a fluid management system that uses ultrafiltration to restore fluid balance in patients experiencing fluid overload, most recently received FDA 510(k) clearance for use in pediatric patients weighing 20 kg or more. Beyond treating heart failure, the device can be of use in these situations with pediatric patients and in critical care, Nuwellis said.
The system is also commonly used in critically ill patients suffering from trauma, burns, severe COVID-19 infection and acute kidney injury.
“2020 was a transformational year for our company, we grew in unexpected ways and expanded our therapeutic focus areas,” Nuwellis president & CEO Nestor Jaramillo, Jr. said in the release. “We are no longer exclusively a heart failure company, as our prior name suggested. Nuwellis represents our mission to better adhere to the needs of all patients suffering from fluid imbalance and reflects our new commercial focus.
“This is an exciting time for our company and represents the growth we have seen and strive to continue to achieve. We will continue to evolve in order to give patients and their providers the best technology to restore fluid balance, and rebranding is a high-level change that reflects our commitment.”